Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235298 · ClinicalTrials.gov registry record · Phase 4
Dapagliflozin Effects on Epicardial Fat
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT02235298 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 100 participants.
The verdict
NCT02235298, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-09 |
| Est. Completion | 2020-09-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02235298
The ClinicalTrials.gov registry entry for NCT02235298 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02235298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02235298 about?
NCT02235298 is a clinical study titled "Dapagliflozin Effects on Epicardial Fat". The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.
What is the current status of trial NCT02235298?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2015-09. Estimated completion is 2020-09-10.
What interventions are being tested in trial NCT02235298?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02235298?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.